The 10th edition of the World Heart Summit took place in Geneva, Switzerland — the epicenter of global health diplomacy — on 16–17 May 2026, ahead of the 79th World Health Assembly.
Summit venue: Biotech Campus, Geneva
| Time | Sessions | ||||||
|---|---|---|---|---|---|---|---|
| 8:30-9:00 | Welcome & Registration | ||||||
| 9:00-9:20 |
Opening of World Heart Summit 2026
Speakers:
|
||||||
| 09:20–10:05 |
2025 moved the needle: what comes next? Discussion on UHC, National Action Plans, and the momentum for cardiovascular health
Aim: The session aims to examine how recent political and policy momentum for cardiovascular health in 2025 can be translated into concrete action, by identifying what must come next to strengthen national action plans, advance universal health coverage, secure sustainable financing, and improve prevention and access to care. Speakers:
|
||||||
| 10:05–10:45 |
Launch of World Heart Report 2026 on congenital heart disease – latest findings
Aim: The aim of this session is to present key findings and insights from the World Heart Report 2026, focusing on congenital heart disease (CHD). The session will highlight the current global and regional burden of CHD and the impacts it has from birth throughout adulthood. It will also showcase successful evidence-based examples of policy interventions and the lived experiences of patients and families of those living with CHD, emphasizing the need for integrated screening, diagnostic and treatment strategies. Speakers:
|
||||||
| 10:45–11:15 | Networking Break | ||||||
| 11:15–12:00 |
Panel: Public trust, AI and the future of digital health
Aim: The session aims to explore how artificial intelligence can be used responsibly to strengthen public trust in digital cardiovascular health, address mis- and disinformation, and clarify the roles of governments and other stakeholders in digital ethics, while encouraging panellists to commit to concrete, practical actions to improve the reliability of digital health information over the coming year. Speakers:
|
||||||
| 12:00–12:45 | Geneva Heart Walk & Outdoor Networking | ||||||
| 12:45–13:45 | Lunch | ||||||
| 13:45–14:30 |
Panel: Nutrition, food systems, and healthy futures
Aim: This session will examine how nutrition policy, food systems, and emerging innovations are shaping cardiovascular health outcomes worldwide. It will explore the roles of regulation, public policy, commercial actors, and medical interventions, and how new therapeutic developments can complement food and nutrition policies. Speakers:
|
||||||
| 14:30–15:15 |
Panel: cities leading for healthy living
Aim: The session aims to highlight how cities can lead on cardiovascular disease prevention and equity through urban policies on mobility, air quality, urban design, access to services and city-level health systems, while inviting city leaders to commit to participation in the City Beat Index as a practical step to accelerate action and accountability. Speakers:
|
||||||
| 15:15–15:45 | Break | ||||||
| 15:45–16:45 |
Panel: LMICs and the global health architecture: challenges and opportunities as aid declines
Aim: The session aims to examine how declining development assistance and shifts in the global health architecture are reshaping the financing and sustainability of health systems in LMICs, and to explore how countries can respond by strengthening domestic health financing, rethinking priorities, and leveraging this transition as an opportunity to elevate historically underfunded issues within national health agendas. Speakers:
|
||||||
| 16:45–17:15 |
Roundtable: next generation and action
Aim: The session aims to amplify the voices of the next generation of health professionals, explore how emerging challenges of the coming decade such as climate change and mental health are reshaping cardiovascular and public health priorities, and inspire concrete action and leadership from the young medical corps. Speakers:
|
| Time | Sessions | ||||||
|---|---|---|---|---|---|---|---|
| 09:00–09:10 | Intro remarks, sum-up of previous day and what to expect today | ||||||
| 09:10-09:40 |
Innovator Spotlight- Interview with health leader(s) on new approaches to prevention and treatment.
Aim: The session aims to spotlight innovative leaders and practical, scalable approaches to cardiovascular prevention and treatment that bridge science, service delivery, and policy, including a focus on solutions that address rare, neglected, and underserved cardiovascular conditions, including through telemedicine, AI-enabled care models, and system integration in LMICs. Speakers:
|
||||||
| 09:40–10:40 |
Ministerial panel: Controlling hypertension at scale
Aim: The session aims to showcase how countries are scaling up hypertension control through concrete policy reforms, investments, and service delivery innovations, including efforts to address pregnancy-related hypertension and gender disparities in cardiovascular care, while encouraging ministers to highlight proven interventions and partnerships that have delivered measurable impact and can be replicated at scale. Speakers:
|
||||||
| 10:40–11:00 | Networking and Coffee break | ||||||
| 11:00–11:30 |
Panel: From nudges to taxes: How to shift behaviour at population scale
Aim: The session aims to examine how environments, policies, and systemic factors shape population health behaviours, exploring strategies from behavioural “nudges” to fiscal measures like taxes that can drive meaningful cardiovascular health improvements at scale, while critically assessing whether current approaches risk treating symptoms rather than addressing underlying structural drivers. Speakers:
|
||||||
| 11:30 – 12:00 |
Panel: Making lipid control a global health priority
Aim: This session will examine the global state of dyslipidaemia management and explore what is needed to translate recent progress into meaningful cardiovascular health gains. Dyslipidaemia remains a major cardiovascular risk factor, with high LDL-C responsible for over 30% of ischaemic heart disease. While momentum is building through initiatives such as WHO’s development of dyslipidaemia guidelines and the EU Safe Hearts call for expanded LDL-C testing and improved screening for Lp(a) and familial hypercholesterolaemia, persistent gaps in diagnosis, treatment, and health system capacity continue to limit impact – underscoring the need for coordinated, system-level action. Speakers:
|
||||||
| 12:00-12:45 |
Closing Plenary – Turning Political Commitments on NCDs into Measurable Action (joint session with NCDA)
Aim: The session aims to explore how renewed global political commitments on NCDs, including cardiovascular disease, can be translated into measurable action, by strengthening accountability, national reporting, civil society engagement, and collaboration among global, regional, and national actors to ensure sustained implementation and real-world impact beyond the UN High-Level Meeting. |
||||||
| 12:45–13:00 | Summit priorities and closing session |
Be part of the World Heart Summit 2026 and join global leaders, experts, and advocates shaping the future of cardiovascular health. Different registration fees apply based on your category, so be sure to check the details and secure your spot on time.
Find out morePresident
World Heart Federation
Jagat Narula, MD, PhD, MACC, FRCP is currently the executive vice president and chief academic officer at UTHealth Houston. He works with the six deans and members of the UTHealth Houston leadership team to advance the academic mission and promote excellence in education and research. This includes leading a diverse team of faculty and administrators to oversee strategic planning and implementation of the university’s education and research platform. Dr. Narula after completing his cardiology fellowship training and PhD (Cardiovascular Immunology) from the All India Institute of Medical Sciences, Delhi, relocated to Massachusetts General Hospital (MGH) and Harvard Medical School in 1989. At MGH, after cardiology, heart failure & transplantation, and nuclear cardiology fellowships and he joined the cardiology faculty. In 1997, he moved to Hahnemann University School of Medicine, Philadelphia, where he was Thomas J. Vischer Professor of Medicine, Chief of the Division of Cardiology, Vice-Chairman of the department of Internal Medicine, and Director of Heart Failure & Transplantation Center. He subsequently joined University of California, Irvine School of Medicine (2003) as Chief of the Division of Cardiology, Associate Dean for Research, and Director of the Cardiovascular Center of the UC Irvine’s Douglas Hospital. He was also the Director of Memorial Heart & Vascular Institute, Long Beach Memorial Hospital, and Medical Director of the Edwards Lifesciences Center for Advanced Cardiovascular Technology in UC Irvine’s Henry Samueli School of Engineering. He moved to Mount Sinai as the Philip J. and Harriet L. Goodhart Chair in Cardiology, and the Director of Cardiovascular Imaging Program in the Mount Sinai’s Zena and Michael A. Wiener Cardiovascular Institute in 2011. Dr. Narula has the unique distinction of being able to combine molecular and subcellular pathology and imaging with clinical imaging of the failing myocardium and high-risk coronary atherosclerotic plaques to develop novel strategies for prevention of cardiovascular disease and promotion of cardiovascular health in developed as well as developing countries. He has specifically contributed to two major areas including heart muscle cell apoptosis in heart failure, and lipid-rich atherosclerotic plaques that are susceptible to rupture and acute coronary events. He has brought novel experimental strategies to bedside and defined their applicability at the community level. He is currently actively involved in numerous population-based heart attack prevention programs including HAPPY [Heart Attack Prevention Program for You]. Based on his expertise in global medicine, he serves on the Advisory Council on Global Prevention of Cardiovascular Diseases of the Institute of Medicine of the National Academies of Sciences. His research has been funded, in part, by the grants from National Institutes of Health. He is considered to be a true translationist and one of the infrequent investigators who has distinction of publishing in the best basic science and the best clinical journals including Science, Nature Medicine, PNAS, New England Journal of Medicine, Lancet, Circulation and JACC. With more than 1000 original research publications or presentations to his credit and more than 35 books or journal supplements edited, Dr. Narula has been awarded as ‘the best young investigator’ on several occasions for his research contributions. His mentoring prowess is exemplified by the fact that 20 of his fellows, working in his research laboratory, have been awarded young investigator awards. He was recently awarded as the Best Educator as also the Innovator in Cardiovascular Medicine by the American College of Cardiology in the year 2012, and was honored as the Master of the American College of Cardiology in March 2013. He has just received the Distinguished Scientist Award 2015 from the American College of Cardiology.President
Healthy Caribbean Coalition
As an Independent Senator in the Parliament of Barbados, appointed by His Excellency, the President of Barbados, and President of the Healthy Caribbean Coalition, I am committed to driving initiatives that address non-communicable diseases and improving public health in the Caribbean region. I bring a wealth of experience in medicine, medical education, and digital media, alongside credentials as a Fellow of the Royal College of Physicians and Fellow of the American College of Physicians. With over three years as Deputy Dean of Recruitment & Outreach at The University of the West Indies, I have contributed to fostering talent and promoting diversity in medical education. My expertise in clinical pharmacology and internal medicine, coupled with a strong foundation in digital media, guides my efforts to collaborate with civil society organizations and global leaders in advancing healthcare outcomes.Secretary General
Swedish Heart and Lung Foundation
Hjärt-Lungfonden has benefited from over 11 years of leadership, with initiatives focused on funding transformative research and promoting public health. By leveraging expertise in PR and organizational leadership, the organization has advanced its mission to combat cardiovascular and pulmonary diseases. Through collaborative efforts and data-driven strategies, the team has empowered impactful healthcare innovations and strengthened public awareness. With a dedication to fostering partnerships and sustainable solutions, Hjärt-Lungfonden is making strides to improve lives and support critical medical advancements.Board Member
ESC ; EACH
https://www.linkedin.com/in/susanna-price-59406155Professor
University of Essex
https://www.linkedin.com/in/mariachiara-di-cesare-28344a116Co-lead
World Heart Report 2026
https://www.linkedin.com/in/krishna-kumar-217341abFounder/CEO and Board Member
Hearts4heart, World Heart Federation
Tanya Hall has over 17 years of experience in the not-for-profit sector, founding Hearts4heart in 2011 after her personal experience with heart disease. As CEO, she has transformed the organization into a leading voice for patient support, education, and advocacy across Australia and New Zealand. Tanya has influenced health policy, expanded access to therapies, and fostered global collaborations with clinicians, policymakers, and industry leaders. She has played a key role in Australia’s focus on patient access to therapies, uniting stakeholders through roundtables and teleconferences. Her goal is to foster stronger collaborations to ensure equitable access to heart health education, prevention, and treatment. Tanya has served on key committees, including the Therapeutic Goods Administration Device Reform, and co-authored several Australian clinical guidelines. Her advocacy work has earned her numerous awards, including the 2023 Advocacy Champion of the Year and Health Industry Hub’s ‘Catalyst for Change’ award.Global Advocate
Children’s HeartLink
• 20+ years of experience in policy advocacy, global health capacity building and health systems strengthening initiatives at the community, hospital and government levels. • Led collaborative efforts in many global and cultural settings with diverse groups of stakeholders, including clinicians, hospital administrators, government officials and policy makers, and patient and family representatives. • Specialized and tertiary health care and quality improvement. • NGO management: strategic planning, operations, governance, program development and evaluation, financial management, donor relations and proposal development. • Built and managed successfully teams, remote and in-person multidisciplinary health team projects in several countries. • Regularly published author in academic and nonacademic journals (https://orcid.org/0000-0002-3209-0261) and invited speaker at international meetings. • Passionate about international development and global health. Thought leader, advocate, strategic partner, connector and catalyst for change. Always learning!President Elect
World Heart Federation
Professor Dorairaj Prabhakaran is an eminent cardiologist, epidemiologist and academician of global repute. He moved beyond the conventional world of clinical cardiology to advance science in the prevention of heart diseases and diabetes in India so that his work could benefit millions of people in this country. He is currently Executive Director, Centre for Chronic Disease Control and the President-Elect of the World Heart Federation. Prof. Prabhakaran has more than 750 publications in prominent scientific journals and has an H‐Index of 126. His work spans from understanding the pathways as to why Indians have a high propensity to CVD and diabetes, the role of air pollution and climate change in chronic diseases, identifying low-cost solutions including digital health, telemedicine and AI, and large-scale capacity building of researchers and physicians. His exceptional contributions spanning Science, Medicine, and Public Health have catapulted the field of Preventive Cardiology in India.Founder
AnginaX AI
Building the future of cardiovascular health for the 21st century. Naman Gosalia is leading a bold, system-level movement to transform heart care from a reactive, symptom-driven model into a world where prevention is the default. He is driving a national and global effort in primary cardiovascular prevention, uniting clinicians, researchers, hospitals, and public-health systems toward one purpose: to save lives before disease ever has the chance to begin. His philosophy is simple and revolutionary: the measure of great healthcare is not how well we treat emergencies but how few emergencies ever reach our doors. Instead of expanding ICUs, he is building the frameworks that ensure fewer people ever need one. Instead of waiting for the heart to fail, he is championing lifelong cardiovascular profiles that allow doctors to intervene early, precisely, and confidently. This mission is rewriting the future of cardiac care aiming to make “sudden heart attack” a phrase the world no longer needs. Every hospital wants clarity. Every doctor wants foresight. Every family deserves prevention. And leadership means creating the world where all three become the standard, not the aspiration. Let’s save lives. Together.Infectious Diseases Doctor and Author
Hospital for Tropical Diseases in London; Book: “Ultra-Processed People”
I’m a professor of Infection and Global Health at University College London, where my research focuses on nutrition and the global food system. I work with UNICEF and the World Health Organization in this area. I’m an infectious diseases doctor in at the Hospital for Tropical Diseases in London. I trained in medicine at Oxford University and have a PhD in molecular virology from UCL. I do broadcasting for the BBC’s for children and adults, on television and radio and my work has won two BAFTAs. I’m the author of the Sunday Times and New York Times bestseller, Ultra-Processed People.President and CEO
Resolve to Save Lives
Dr. Tom Frieden is a physician trained in internal medicine, infectious diseases, public health, and epidemiology. Dr. Frieden is now the President and Chief Executive Officer of Resolve to Save Lives, which works with partners to accelerate action against the world's leading health threats and save millions of lives Dr. Frieden was the Director of the Centers for Disease Control and Prevention (CDC) from 2009 – 2017. At the CDC, Dr. Frieden oversaw the work that helped end the 2014 West Africa Ebola epidemic. He began his public health career in New York City confronting the largest outbreak of multi-drug resistant tuberculosis to occur in the US. He was then assigned to India, on loan from the Centers for Disease Control and Prevention, where he helped scale up a program for effective tuberculosis diagnosis, treatment, and monitoring. Asked to return to New York City to become Mayor Mike Bloomberg’s Health Commissioner, he directed efforts to reduce smoking and other leading causes of death that increased life expectancy by 3 years.Scientist
World Health Organization
Scientist working on climate change and health since 1999. Head of the Climate Change and Health Unit at the World Health Organization since 2010, coordinating across WHO’s leadership, technical and country support work to advance health protection from climate risks, and to gain the huge health benefits that come from a transition to clean, cheap and sustainable energy sources . Lead author on three reports of the Intergovernmental Panel on Climate Change, Member of the UN National Academies of Medicine. Occasional cyclist for individual and public health, for the planet, and for pleasure. On Bluesky at @diarmidcl.bsky.socialChief Physician of the Cardiovascular Surgery Department
Hôpitaux Universitaires de Genève, HUG
Cardiac Surgeon and Inventor of the transapical access for TAVI. This medical technology has saved over 30'000 lives. Serving as one of the most experienced cardiac surgery chiefs of Switzerland. Pioneer of transcatheter valve therapies and editor of the first textbook called Transcatheter Valve Therapies he significantly contributed to the expansion of one of the most promissing field in cardiovascular medicine. He founded Endoheart AG, A Swiss medtech start-up active in the field of cutting edge endovascular therapies for the cure of heart disease. Christoph Huber is serving as vice president of the swiss society of cardiac surgery.CEO
CeHDI
Dr Haileyesus Getahun is the Founder and CEO of the Global Centre for Health Diplomacy and Inclusion (CeHDI), a Geneva-based foundation dedicated to amplifying the priorities and voices of the Global South in global health governance, advancing the right to health, and global health equity. He also serve as the founding CEO of the Health Development Partnership for Africa and the Caribbean (HeDPAC), an initiative established in the wake of the COVID-19 pandemic to strengthen South-South cooperation and strategically aligned health partnerships between Africa and the Caribbean. Prior to these roles, Dr Getahun was the founding Director of the Global AMR Coordination and the Quadripartite Joint Secretariat on Antimicrobial Resistance (AMR), hosted by the World Health Organisation and bringing together FAO, UNEP, WHO, and WOAH. In this capacity, he led the global One Health, multisectoral response to AMR and guided the establishment of the Global Leaders Group on AMR, the AMR Multi-Stakeholder Partnership Platform, and the AMR Multi-Partner Trust Fund—three landmark global structures that transformed the global AMR response. During his tenure, he drove several high-impact innovations in the global AMR agenda, including the transformation of World Antibiotic Awareness Week into World AMR Awareness Week, now observed annually from 18–24 November; and the development of the Priority One Health Research Agenda for AMR. Dr. Getahun also served as Director of the Secretariat of the United Nations Interagency Coordination Group on Antimicrobial Resistance, established by the UN Secretary-General and coordinated the landmark 2019 report that helped shape the global policy and political responses to AMR. Earlier in his career, he held senior leadership roles in WHO’s Global Tuberculosis Programme, leading the organization’s work on TB/HIV and community-based care worldwide, including authoring the 2004 interim TB/HIV policy, whose implementation helped avert an estimated 9.8 million deaths between 2005 and 2024. Across his career, Dr Getahun has led international teams, shaped global health policy, convened senior political leaders, and built high-impact partnerships and institutions across the UN system, governments, and global institutions.Professor and Board Member
University of Nairobi; World Heart Federation
https://www.researchgate.net/profile/Elijah-OgolaPatient Advocate
Rheumatic Heart Disease
https://www.linkedin.com/in/anu-gomanju-bph-ma-mph-in-global-health-68407369Paediatric Cardiologist
Red Cross War Memorial Children’s Hospital, South Africa
https://www.linkedin.com/in/liesl-zuhlke-7654aa23Co-CEO
Financing Alliance for Health
I’m a global non-profit executive, operator, and strategist with over 20 years of experience leading complex, multi-country organizations across Africa and beyond. Currently, I serve as Co-CEO of Financing Alliance for Health, where I work at the intersection of strategy, operations, governance, and resource mobilization; helping mission-driven initiatives move from vision to execution. My work spans organizational design, fiscal sponsorship, donor partnerships, risk management, and building systems that allow organizations to scale sustainably while staying rooted in local leadership. A consistent thread in my career has been strengthening the “backbone” of impact : structures, people, processes, and funding models that make good ideas last. Alongside my executive role, I’m passionate about mentoring and knowledge-sharing, particularly with women navigating leadership, career growth, and work-life integration. I believe ambition and balance are not mutually exclusive, and that clarity, systems, and self-trust are powerful tools for building a life and career by design. I’m known for being strategic, grounded, and deeply collaborative and able to zoom out to big-picture vision while staying close to the operational details that matter. If you’re interested in conversations on non-profit leadership, governance, systems thinking, or designing a career with intention, you’re in the right place.President
Youth Health Organization
A public health advocate and civil society leader passionate about advancing health equity and meaningful youth participation. With more than a decade of experience in social impact and health promotion and advocacy, I currently serve as Program director of CAZAS and President of the International Youth Health Organization, where I lead efforts to strengthen health services and policies and youth engagement in health policy and program development across Montenegro, Europe and beyond. My journey began in Montenegro as a youth health educator, and over the years I’ve had the privilege to coordinate national and international initiatives addressing HIV prevention, mental health, reproductive rights, and non-communicable diseases. What drives me most is creating spaces where citizens, especially youth, can influence decisions that shape their wellbeing. I believe that inclusive, transparent, and forward-thinking health systems start with empowered individuals who dare to reimagine how health and equity are defined.CEO and Co-Founder
OWKIN
I am a creative and dynamic Medical Doctor focused on bringing the first infrastructure for biology ASIProfessor
University of Sydney
Clara Chow is a Cardiologist at Westmead hospital, Professor of Medicine, at the University of Sydney, and Academic Director of the Westmead Applied Research Centre. At Westmead, she is Program Director, Community Based Cardiac Services with responsibilities for the Rapid Access Cardiology Services which she instigated in 2015. She also hold honorary roles as the Academic co-Director CPC Westmead, and professorial fellow at the George Institute for Global Health. She was President of the Cardiac Society Australia and New Zealand in 2021-3 and its first female president. She was the inaugural Director of the Australian Stroke and Heart Research Accelerator. She has a PhD from the University of Sydney, Australia in cardiovascular epidemiology and international public Health and a Postdoc from McMaster University, Canada. Clara’s research focuses on the prevention of cardiovascular disease, innovation in delivery of cardiovascular care and the design and evaluation of digital health interventions. Her research track includes >350 scientific publications including papers in top-tier journals such as Lancet, JAMA and NEJM. Clara was appointed a Member of the Order of Australia (AM) in 2023. She currently serves on the Boards of the WSLHD and the National Heart Foundation. Her clinical interests are in cardiac imaging particularly cardiac CT and echo.Prevention Project Director
Novo Nordisk
+20 years experience in public-private partnership, corporate sustainability strategy and communication. Specialties: Social partnerships and strategic stakeholder engagement, Corporate sustainability strategy and communication, NCD prevention and health promotion, childhood obesity, environmental/climate communication and advocacy, green accounts, eco-labels, training and education, private sector development Africa and AsiaAlternate Minister of Health
Greece
Eirini Agapidaki, Alternate Minister of Health (Greece) Eirini Agapidaki is a Psychologist, with an MSc in Health Promotion and Education from the Medical School of the National and Kapodistrian University of Athens; and a PhD in Health Psychology from the same university. She has also specialized in matters of prevention of mental disorders and promotion of mental health. In addition, she has many years of teaching and research experience in the fields of public health policy, public health research methodology and mental health promotion – in the context of national, European and international research programs. She has worked for many years as a research associate at the Department of Hygiene, Epidemiology and Medical Statistics, of the Medical School of the National and Kapodistrian University of Athens. In recent years she was elected and served as a Lecturer in Public Health, at the Medical School of the European University of Cyprus. In 2019, she resigned from her academic role in order to take up her duties as the Special Secretary for the Protection of Unaccompanied Minors (at the Ministry of Migration and Asylum). At the end of December 2022, she assumed the duties of Secretary General of Public Health, and since July 2023 she serves as the Alternate Minister of Health and as a member of the Greek Parliament. She has written and published research papers in peer-reviewed scientific journals, while she has presented the results of her research papers at many national and international conferences.Minister of Health
Egypt
Founder
Global Health Centre at the Graduate Institute in Geneva
I am a member of the Global Preparedness Monitoring Board and co chair of The World Health Summit Council. I am director of the digital transformations for Health LAB. I advise on matters of global health governance and have launched training in global health diplomacy. I have contributed to as well as initiated many global health innovations. Present interests relate to health and geopolitics, planetary health and digital determinants of health.Nicotine Tobacco Alcohol and Drugs Expert Group Member
World Heart Federation
Researcher
Paris Cardiovascular Research Centre (PARCC)
https://www.linkedin.com/in/akouamiviFounder
Heart Sistas
https://www.linkedin.com/in/hyvelle-ferguson-davis-1890961b3Executive Director of Global Health Policy
MSD
Amiee Aloi is a leading international public policy and government affairs professional with particular expertise in health policy and development. Amiee is currently Executive Director, Global Public Policy at Merck. Previously, she was Director, Advocacy and Government Relations at Gates Ventures, the private office of Bill Gates. Prior to that, she was Deputy Vice President for International Advocacy at the Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry association representing innovative global biopharmaceutical companies. In this capacity, Amiee was responsible for strategic planning, implementation, and coordination of the biopharmaceutical association’s advocacy efforts that address industry’s international trade priorities. Amiee has strong analytical skills, particularly with respect to legislation, trade, and policy documents, and strong written and verbal communication skills. She has lived in Delhi, India and has a deep understanding of the business and political environment in Asia. Previously, she worked as Associate Vice President at PhRMA where she lead industry's advocacy activities in India across a range of policy issues including intellectual property and innovation, market access and pricing, and clinical research. She's also worked as Director of Policy at PhRMA where she worked to promote strategies demonstrating the value of innovative medicines across the U.S. health care system, including Medicare, Medicaid, Veteran's Affairs, and health insurance exchanges. Prior to joining PhRMA, Amiee worked at Avalere Health, a leading healthcare advisory company, where she provided research and analysis on coverage, reimbursement, and policy issues facing biopharmaceutical and medical device companies. Specialties: policy, international affairs, India, advocacy, pharmaceutical policy, trade policy, public health policy, international development, intellectual property policy, access to medicines policy, stakeholder engagement strategy, government relations, advocacy and strategy development.Founder and CEO
Heart Health India Foundation
https://www.linkedin.com/in/ram-khandelwal-b90a668/
